Ultragenyx to Acquire Mereo BioPharma for $1 Billion
Ticker: MREO · Form: 8-K · Filed: Jul 10, 2025 · CIK: 1719714
| Field | Detail |
|---|---|
| Company | Mereo Biopharma Group PLC (MREO) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, biotech
Related Tickers: RARE
TL;DR
Ultragenyx is buying Mereo BioPharma for $1B cash & stock, deal expected Q4 2025.
AI Summary
Mereo BioPharma Group plc announced on July 9, 2025, that it has entered into a definitive agreement to be acquired by Ultragenyx Pharmaceutical Inc. for approximately $1.0 billion in cash and stock. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions and regulatory approvals.
Why It Matters
This acquisition by Ultragenyx Pharmaceutical Inc. could significantly expand its rare disease pipeline, potentially bringing new treatments to patients and impacting the competitive landscape in the rare disease sector.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions and regulatory approvals, which introduces uncertainty regarding the completion of the transaction.
Key Numbers
- $1.0 billion — Acquisition Value (Total cash and stock consideration for the acquisition of Mereo BioPharma.)
- Q4 2025 — Expected Closing (Anticipated timeframe for the completion of the acquisition.)
Key Players & Entities
- Mereo BioPharma Group plc (company) — Acquired company
- Ultragenyx Pharmaceutical Inc. (company) — Acquiring company
- $1.0 billion (dollar_amount) — Acquisition price
- July 9, 2025 (date) — Date of agreement
- fourth quarter of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition agreement between Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc?
The definitive agreement states that Ultragenyx Pharmaceutical Inc. will acquire Mereo BioPharma Group plc for approximately $1.0 billion in cash and stock.
When is the acquisition expected to be completed?
The transaction is anticipated to close in the fourth quarter of 2025.
What are the primary conditions for the acquisition to be finalized?
The acquisition is subject to customary closing conditions and regulatory approvals.
What is the exact date the agreement was reported?
The report indicates the date of the earliest event reported is July 9, 2025.
What is the principal executive office address for Mereo BioPharma Group plc?
The principal executive offices are located at 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 10, 2025 regarding Mereo BioPharma Group plc (MREO).